Head-to-head evidence
BCD-281 vs Divozilimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
BCD-281
Developed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07321093 (registry estimate)
Divozilimab
Developed by Biocad
NCT06987851 · Phase 3 · completed
This was an open-label, single-group extension study without a comparator, enrolling 44 participants who continued from the prior BCD-132-4/MIRANTIBUS study after earlier BCD-132 treatment. Its primary endpoint was the clinical measure of annualized relapse rate at 48 and 96 weeks, but the result was not reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-281's landscape · Divozilimab's landscape